Skip to main content
MBI logo

MBI — Investor Relations & Filings

Ticker · 1783 ISIN · TW0001783009 TW Manufacturing
Open in API
Filings indexed 1,694 across all filing types
Latest filing 2024-11-12 Capital/Financing Update
Country TW Taiwan
Listing TW 1783

About MBI

www.mbi.com.tw

Maxigen Biotech Inc. (MBI) is a medical device manufacturer specializing in the research, development, and production of biopolymer-based solutions, primarily focusing on collagen matrix and hyaluronic acid technologies. The company provides a comprehensive range of medical devices across multiple clinical disciplines, including orthopedics, aesthetics, ophthalmology, and wound care. Key products include hyaluronic acid intra-articular injections, dermal fillers, ophthalmic viscoelastics, collagen wound dressings, dental membranes, and synthetic bone grafts. In addition to its proprietary brands, MBI offers global OEM/ODM and customization services. The company adheres to international quality standards, holding certifications such as CE, FDA, NMPA, and MDSAP. MBI leverages its expertise in biopolymer science to deliver innovative medical and skincare products to international markets.

Recent filings

Filing Released Lang Actions
113年第3季大陸投資
Capital/Financing Update Classification · 95% confidence The document is a detailed tabular disclosure of investment amounts and related financial figures concerning investments in mainland China by a Taiwanese listed company. It includes specific financial data such as capital amounts, investment methods, cumulative investment amounts, recognized investment gains or losses, and regulatory approval limits. The document is relatively short (1302 characters) and focuses on investment details rather than a full financial report or announcement. It does not appear to be an announcement of a report publication, nor a certification or a general regulatory filing. The content is specific to capital investment updates and regulatory compliance related to cross-border investments. Therefore, the document best fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including investment disclosures.
2024-11-12 Chinese
113年11月法人說明會簡報 — 178320241108E001.pdf
Investor Presentation Classification · 95% confidence The document is titled '04 2024 法人說明會' which translates to 'April 2024 Institutional Investor Meeting' or 'Investor Presentation'. It contains detailed financial data for Q3 2024 including consolidated financial reports, sales breakdowns, marketing events, and forward-looking statements under a 'Safe Harbor Notice'. The presence of detailed financial tables, marketing event schedules, and forward-looking statements is typical of an investor presentation. The document length is 5136 characters, which is sufficient to contain substantive financial data and analysis, not just a brief announcement or certification. There is no indication that this is a full annual report or an interim report filing; rather, it is a presentation aimed at investors summarizing recent financial performance and outlook. Therefore, the document best fits the category of an Investor Presentation (IP).
2024-11-08 Chinese
113年11月法人說明會簡報 — 178320241108M001.pdf
Regulatory Filings
2024-11-08 Chinese
113年11月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a scheduled investor presentation (法人說明會) including date, time, location, summary, and links to presentation materials and video. The content is focused on an investor presentation event rather than a full financial report or regulatory filing. The document length is short (755 characters) and it provides links to presentation PDFs and video, consistent with an Investor Presentation (IP) filing type.
2024-11-08 Chinese
113年10月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (和康生) providing data on loan balances and guarantee information for the current and previous months, including limits and cumulative amounts. The content is concise (612 characters) and focuses on specific financial data related to loans and guarantees rather than a comprehensive financial report or announcement. It does not contain full financial statements or detailed analysis typical of Annual Reports (10-K) or Interim Reports (IR). It also does not fit categories like Audit Report, Earnings Release, or Management Reports. Given the nature of the data and the format, this is best classified as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-11-07 Chinese
113年10月營業收入
Fund Information / Factsheet Classification · 85% confidence The document is a revenue summary report from a listed company, showing monthly and cumulative net operating revenue figures with percentage changes compared to the previous year. It includes notes on accounting standards (IFRS) and reporting requirements. The document length is short (766 characters) and it primarily provides summarized financial data without detailed financial statements or analysis. It does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It is also not an announcement of a report publication but a direct data disclosure. Given the nature of the content as a brief financial summary, it best fits the category of Fund Information / Factsheet (FS), which is for brief summaries of key company financials and market info.
2024-11-07 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.